Research
Hormonal
Semaglutide (subcutaneous and oral) demonstrates cardiovascular safety (non-inferiority) and potential renal benefits in high-risk Type 2 Diabetes patients, though it may increase retinopathy complications.
For those with Type 2 Diabetes and heart disease risk, semaglutide is safe for the heart and may protect kidney function. However, patients with existing diabetic eye disease should be monitored closely as rapid blood sugar improvement can sometimes worsen retinopathy.
StrongQualifiesHIGH confidence
The primary outcome composite (first occurrence of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke) occurred in 6.6% in the semaglutide group vs. 8.9% in the placebo group (P<0.0001 for noninferiority).
Why this rating
Based on SUSTAIN-6 and PIONEER-6 cardiovascular outcome trials.
Source
Future perspectives in diabesity treatment: Semaglutide, a glucagon‑like peptide 1 receptor agonist (Review)
Mariana Cornelia Tilinca et al. · Experimental and Therapeutic Medicine · 2021
narrative_reviewCited 26×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →